Prediabetes History of Treatment Over Decades

Before There Was a Name: Glucose Abnormalities in the Pre-1979 Era

Before 1979, physicians had no agreed-upon term for blood sugar that was elevated but below the diabetes threshold. That gap mattered clinically. Patients fell through a diagnostic void, receiving inconsistent advice or nothing at all.

Early Observations of "Borderline Diabetes"

The concept of an intermediate glucose state appeared in medical literature as early as the 1950s, often called "borderline diabetes," "latent diabetes," or "chemical diabetes." These labels carried different meanings depending on the clinician using them, making research comparisons nearly impossible. A 1960 review in the American Diabetes Association's journal noted that oral glucose tolerance test (OGTT) interpretation varied so widely between laboratories that a single patient might receive a diabetes diagnosis at one center and a clean bill of health at another [1].

The 1979 WHO/NDDG Classification

The National Diabetes Data Group (NDDG) published a formal classification system in 1979 that introduced standardized glucose cutoffs. For the first time, "Impaired Glucose Tolerance" (IGT) described a two-hour post-load glucose of 140 to 199 mg/dL on a 75g OGTT [2]. This classification was quickly endorsed by the World Health Organization and became the first internationally recognized label for what we now call prediabetes. Treatment at this stage remained almost entirely lifestyle advice, and guidance was vague: eat less sugar, exercise more, lose weight. No clinical trial had tested whether any intervention could actually slow progression to diabetes.

The 1980s and 1990s: Epidemiology Builds the Case

With a definition in hand, researchers began tracking IGT cohorts. The results were alarming.

Prospective Cohort Data

The Da Qing IGT and Diabetes Study, launched in China in 1986, enrolled 577 adults with IGT and randomly assigned them to control, diet, exercise, or diet-plus-exercise groups [3]. Results published in 1997 showed that diet alone reduced the six-year incidence of type 2 diabetes by 31%, exercise alone by 46%, and the combined intervention by 42%. These were the first controlled data demonstrating that IGT was modifiable, not merely a passive way-station to diabetes.

The Malmö Feasibility Study

In Sweden, the Malmö Preventive Project showed similar signals. A subset of 181 men with IGT who received a structured diet and exercise program had a five-year diabetes incidence of roughly 11%, compared with approximately 29% in an untreated reference group [4]. Mortality in the intervention group was also lower, a finding that would not be replicated with statistical power until later, larger trials.

IFG Enters the Lexicon: 1997 ADA Criteria

The American Diabetes Association revised its diagnostic criteria in 1997, adding "Impaired Fasting Glucose" (IFG), defined then as fasting glucose 110 to 125 mg/dL, alongside IGT. This change simplified screening by eliminating the need for a full OGTT to identify at-risk patients [5]. The ADA Expert Committee noted that the two conditions (IFG and IGT) overlap but are not identical, capturing different populations with different risk profiles, a distinction that still shapes clinical decision-making today.

2002: The Turning Point

The year 2002 produced two publications that permanently changed prediabetes management.

The Diabetes Prevention Program (DPP)

The DPP enrolled 3,234 adults with IGT and elevated fasting glucose across 27 U.S. Centers. Participants were randomly assigned to intensive lifestyle change (ILS), metformin 850 mg twice daily, or placebo. After a mean follow-up of 2.8 years, ILS reduced progression to type 2 diabetes by 58% compared with placebo (P<0.001), and metformin reduced progression by 31% (P<0.001) [6]. The lifestyle arm targeted at least 150 minutes per week of moderate-intensity physical activity and 7% weight loss. These specific numbers became the backbone of every major clinical guideline published in the next two decades.

The DPP authors wrote, "The Diabetes Prevention Program has demonstrated that type 2 diabetes can be prevented or delayed in persons at high risk" [6]. That sentence, direct and unqualified, reoriented clinical practice.

ADA 2002 Standards of Care

Immediately following the DPP publication, the ADA 2002 Standards of Medical Care in Diabetes became the first ADA guideline to formally recommend metformin as an option for high-risk individuals with prediabetes who could not sustain lifestyle change [7]. This was a significant shift. Pharmacotherapy was now on the table for a condition that had, for 20 years, been managed with diet pamphlets alone.

2003 to 2009: Guideline Expansion and Drug Trials

Orlistat and the XENDOS Trial

Following the DPP, researchers tested other agents. The XENDOS trial (N=3,305) showed that orlistat 120 mg three times daily combined with lifestyle changes reduced the four-year cumulative incidence of type 2 diabetes by 37.3% compared with lifestyle plus placebo in obese adults, many of whom had IGT [8]. Orlistat was FDA-approved for obesity in 1999, but XENDOS provided the first large dataset supporting its use in a prediabetes-adjacent population. The drug never achieved widespread adoption for prediabetes specifically, due to gastrointestinal side effects and the administrative complexity of three-times-daily dosing.

ACE Inhibitors and ARBs: A Failed Hypothesis

The DREAM trial (2006, N=5,269) tested whether ramipril or rosiglitazone could prevent diabetes in people with IFG or IGT. Ramipril did not significantly reduce diabetes incidence (hazard ratio 0.91, 95% CI 0.81 to 1.03), but rosiglitazone reduced it by 60% [9]. That rosiglitazone result was never translated into a guideline recommendation because the drug's cardiovascular safety signal, which emerged in a 2007 NEJM meta-analysis by Nissen and Wolski, effectively ended its use [10]. The episode demonstrated a recurring tension in prediabetes pharmacology: metabolic efficacy does not guarantee safety approval.

HbA1c Added as a Diagnostic Criterion: 2010

In 2010, the ADA added HbA1c to the diagnostic framework, defining prediabetes as HbA1c 5.7 to 6.4% [11]. This change made screening substantially easier because HbA1c requires no fasting and reflects average glucose over 90 days rather than a single point measurement. The International Expert Committee that proposed this cut-off acknowledged that the 5.7% lower bound was chosen partly for practical reasons, not solely on risk-curve biology. An HbA1c of 6.0 to 6.4% carries a meaningfully higher annual conversion rate to diabetes than 5.7 to 5.9%, a nuance that ADA guidelines began to address more explicitly in their 2015 revision.

2010 to 2018: Scale-Up and Structured Programs

National DPP

The CDC launched the National Diabetes Prevention Program (National DPP) in 2010, based directly on the DPP curriculum. By 2018, CMS began reimbursing the year-long structured lifestyle program for Medicare beneficiaries with prediabetes, the first time a prevention intervention of this kind was covered under federal insurance [12]. Coverage expansion was significant: roughly 84 million U.S. Adults had prediabetes at that time, and fewer than 5% had ever participated in a structured prevention program.

Thiazolidinediones After Rosiglitazone

With rosiglitazone sidelined, pioglitazone attracted attention. The ACT NOW trial (2011, N=602) showed that pioglitazone 45 mg daily reduced conversion from IGT to diabetes by 72% over a median of 2.4 years [13]. Fluid retention, weight gain, and a possible increased risk of bladder cancer tempered enthusiasm. Pioglitazone for prediabetes never received FDA approval for that indication and remained off-label.

Alpha-Glucosidase Inhibitors

Acarbose gained modest attention through the STOP-NIDDM trial (N=1,429), which showed a 25% relative risk reduction in diabetes progression among adults with IGT [14]. Acarbose is approved by the FDA for type 2 diabetes but not for prediabetes. Its use in the U.S. Remained limited due to gastrointestinal tolerability issues, though uptake was stronger in parts of Asia where carbohydrate-dense diets made its post-meal glucose-blunting mechanism particularly practical.

DPP Outcomes Study: 15-Year Data

The DPP Outcomes Study, published in 2015, followed the original cohort for a cumulative median of 15 years. The lifestyle group retained a 27% lower diabetes incidence than placebo, even after the blinded phase ended and participants in all groups received some lifestyle support [15]. This long-term follow-up data answered a critical question: benefits from intensive lifestyle intervention persisted, they were not just a short-term effect that washed out as soon as structured support ended.

2019 to 2022: GLP-1 Receptor Agonists Enter the Conversation

Semaglutide and Prediabetes Remission

The STEP-1 trial (N=1,961) tested subcutaneous semaglutide 2.4 mg weekly in adults with obesity (BMI 30 or above, or 27 with a weight-related comorbidity). After 68 weeks, 84.1% of participants who had prediabetes at baseline returned to normoglycemia compared with 47.8% in the placebo group [16]. Mean weight loss was 14.9% with semaglutide vs. 2.4% with placebo. Semaglutide is not FDA-approved for prediabetes specifically, but these data catalyzed prescribing in high-risk individuals who also met criteria for obesity treatment.

Tirzepatide in the SURMOUNT-1 Trial

SURMOUNT-1 (N=2,539) tested tirzepatide, a dual GIP/GLP-1 receptor agonist, in adults with obesity without diabetes. At 72 weeks, 95.3% of participants with baseline prediabetes achieved normoglycemia on the 15 mg dose vs. 61.9% on placebo [17]. The FDA approved tirzepatide (Zepbound) for chronic weight management in November 2023. Because prediabetes remission was a secondary endpoint rather than a primary one, no approved labeling addresses prediabetes directly, but the magnitude of glycemic normalization in these trials was unprecedented in the prediabetes literature.

A Practical Framework for Risk-Stratified Prediabetes Intervention (2024 Clinical Perspective)

Clinicians managing prediabetes today operate across three risk tiers that emerged from combining DPP-era data with modern pharmacotherapy options:

Tier 1 (HbA1c 5.7 to 5.9%, no other major risk factors): Intensive lifestyle modification alone, 150 minutes per week of moderate aerobic activity, 5 to 7% body weight reduction, Mediterranean or low-glycemic dietary pattern. Recheck HbA1c at 6 to 12 months.

Tier 2 (HbA1c 6.0 to 6.4%, or HbA1c 5.7 to 5.9% plus BMI 35 or above, or history of gestational diabetes): Lifestyle modification plus metformin 500 to 1,000 mg twice daily. The ADA's 2024 Standards of Care designate this group as highest priority for metformin given cost-effectiveness and long-term safety data spanning more than 20 years [18].

Tier 3 (HbA1c 6.0 to 6.4% plus BMI 30 or above, rapid HbA1c trajectory, or multiple cardiovascular risk factors): Lifestyle modification with consideration of a GLP-1 or dual GIP/GLP-1 agonist, with metformin as an adjunct or alternative. Referral to a registered dietitian and a structured CDC-recognized National DPP program is appropriate at all tiers.

This three-tier model is not an official ADA classification. It represents a synthesis of current guideline language and trial data intended to help clinicians prioritize intensity of intervention.

2023 to 2025: Current Guidelines and Emerging Agents

ADA 2024 Standards of Care

The ADA 2024 Standards of Medical Care in Diabetes retained metformin as the only pharmacologic agent with a formal recommendation for prediabetes prevention. Metformin carries a Grade A recommendation for adults aged 25 to 59 with BMI 35 or above, fasting glucose 110 to 125 mg/dL, or HbA1c 6.0 to 6.4% [18]. The same document acknowledges that GLP-1 receptor agonists and tirzepatide produce glycemic normalization in clinical trials but stops short of a formal prediabetes-specific recommendation, citing the need for trials powered with diabetes prevention as a primary endpoint.

USPSTF 2021 Update

The U.S. Preventive Services Task Force updated its prediabetes and type 2 diabetes screening recommendation in 2021, lowering the screening age from 40 to 35 for adults with overweight or obesity [19]. The task force assigned a Grade B recommendation to offering or referring at-risk adults to intensive behavioral counseling interventions, based on a systematic review covering 30 trials and 43,141 participants.

Oral Semaglutide and the PIONEER Program

Oral semaglutide (Rybelsus) is approved for type 2 diabetes at doses up to 14 mg daily. The PIONEER 10 trial examined its glucose-lowering profile in Japanese patients, and ongoing work is examining whether an oral GLP-1 formulation might lower the access barrier for prediabetes pharmacotherapy [20]. No FDA approval for a prediabetes indication has been granted as of early 2025.

Continuous Glucose Monitoring in Prediabetes

Consumer-grade continuous glucose monitors (CGMs) such as the Dexterity Stelo and Abbott Lingo received FDA clearance in 2024 for over-the-counter use without a prescription. These devices can detect post-meal glucose excursions above 140 mg/dL that a fasting HbA1c would miss entirely, potentially identifying individuals at the earliest stage of glucose dysregulation [21]. How CGM data will be incorporated into screening thresholds and intervention triggers remains an open clinical question, but the devices are already changing how high-engagement patients self-monitor.

Reversibility: What "Treating" Prediabetes Actually Means

Regression to Normoglycemia

A persistent clinical misconception frames prediabetes as an inevitable precursor to type 2 diabetes. In the DPP lifestyle arm, 38% of participants returned to normal glucose regulation after one year [6]. In STEP-1, 84.1% of prediabetes participants normalized HbA1c on semaglutide [16]. Regression is common. It is not a guarantee of permanent remission, because without sustained behavioral or pharmacologic intervention, relapse is frequent, but regression is achievable.

Cardiovascular Risk Reduction

The Da Qing 30-year follow-up (published 2019) showed that participants originally randomized to lifestyle intervention had a 26% lower rate of cardiovascular disease mortality and a 33% lower rate of all-cause mortality over three decades compared with controls [22]. Treatment of prediabetes is not only about preventing diabetes. It may extend life.

Gestational Diabetes as a Special Case

Women who develop gestational diabetes mellitus (GDM) carry a 35 to 60% lifetime risk of progressing to type 2 diabetes. Postpartum glucose testing, recommended by ACOG at 4 to 12 weeks after delivery, identifies those with residual prediabetes [23]. Despite this clear window, postpartum testing rates remain below 40% in most U.S. Health systems, representing one of the largest missed-intervention opportunities in preventive endocrinology.